Plain-English translation of NCT06565689 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first human study of a new medication called designed to treat B-cell non-Hodgkin lymphoma — a blood cancer — in patients whose disease has come back or stopped responding to earlier treatments. Researchers want to learn whether this medication is safe, how your body processes it, and whether it can help shrink your cancer. The study will enroll about 48 patients.
People with B-cell non-Hodgkin lymphoma that has relapsed or become resistant to standard treatments have very limited options. This medication represents a potentially new way to attack these hard-to-treat cancers, and researchers need to test whether it works safely in humans.
You likely qualify if…
You likely don't qualify if…
You will receive as an intravenous infusion (through an IV in your arm) once every two weeks. Each treatment cycle lasts 4 weeks, and you will continue receiving the medication for up to 6 cycles — about 6 months total — unless your cancer stops responding, you experience intolerable side effects, or your doctor decides to stop treatment. Throughout the study, you will have regular blood tests, scans, and check-ins with your doctor to monitor how you are responding and watch for any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Excyte Biopharma Ltd
Enrollment target
~48 participants
Started
May 2023
Primary completion
December 2028
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yuankai Shi, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.